Press Releases

Date Title and Summary View
Toggle Summary Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles
Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. — July 9, 2009 — Revance Therapeutics, Inc. (“Revance”) today announces that RT001, a
View HTML
Toggle Summary Revance Secures $8 Million in New Financing
Revance Secures $8 Million in New Financing CONTACT: Revance Therapeutics, Inc. Niquette Hunt Vice President, Marketing & Business Development (510) 742-3400 Newark, Calif. November 18, 2008 — Revance Therapeutics, Inc. (“Revance”) today announced an agreement with Leader Ventures and Horizon
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools